Drug Facts
Composition & Profile
Identifiers & Packaging
HOW SUPPLIED NDC: 71335-1914-1: 20 TABLETs in a BOTTLE NDC: 71335-1914-2: 30 TABLETs in a BOTTLE NDC: 71335-1914-3: 40 TABLETs in a BOTTLE NDC: 71335-1914-4: 90 TABLETs in a BOTTLE NDC: 71335-1914-5: 60 TABLETs in a BOTTLE NDC: 71335-1914-6: 100 TABLETs in a BOTTLE NDC: 71335-1914-7: 14 TABLETs in a BOTTLE NDC: 71335-1914-8: 7 TABLETs in a BOTTLE NDC: 71335-1914-9: 120 TABLETs in a BOTTLE; Chlorzoxazone 500mg Tablet Label
- HOW SUPPLIED NDC: 71335-1914-1: 20 TABLETs in a BOTTLE NDC: 71335-1914-2: 30 TABLETs in a BOTTLE NDC: 71335-1914-3: 40 TABLETs in a BOTTLE NDC: 71335-1914-4: 90 TABLETs in a BOTTLE NDC: 71335-1914-5: 60 TABLETs in a BOTTLE NDC: 71335-1914-6: 100 TABLETs in a BOTTLE NDC: 71335-1914-7: 14 TABLETs in a BOTTLE NDC: 71335-1914-8: 7 TABLETs in a BOTTLE NDC: 71335-1914-9: 120 TABLETs in a BOTTLE
- Chlorzoxazone 500mg Tablet Label
Overview
Chlorzoxazone USP is a centrally acting skeletal muscle relaxant, available as tablets of 500 mg for oral administration. Its chemical name is 5-Chloro-2-benzoxazolinone, and its structural formula is: C 7 H 4 CINO 2 MW 169.57 Chlorzoxazone USP is a white or practically white, practically odorless, crystalline powder. Chlorzoxazone is slightly soluble in water; sparingly soluble in alcohol, in isopropyl alcohol, and in methanol; soluble in solutions of alkali hydroxides and ammonia. Chlorzoxazone tablets contain the inactive ingredients Pregelatinized Starch, Croscarmellose Sodium, Microcrystalline Cellulose, Docusate Sodium, Sodium Benzoate, Colloidal Silicon dioxide, Magnesium Stearate. structure
Indications & Usage
INDICATIONS & USAGE Chlorzoxazone is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions. The mode of action of this drug has not been clearly identified, but may be related to its sedative properties. Chlorzoxazone does not directly relax tense skeletal muscles in man.
Dosage & Administration
DOSAGE & ADMINISTRATION Usual Adult Dosage One tablet three or four times daily. If adequate response is not obtained with this dose, it may be increased to one and one-half tablets (750 mg) three or four times daily. As improvement occurs dosage can usually be reduced.
Warnings & Precautions
WARNINGS Serious (including fatal) hepatocellular toxicity has been reported rarely in patients receiving chlorzoxazone. The mechanism is unknown but appears to be idiosyncratic and unpredictable. Factors predisposing patients to this rare event are not known. Patients should be instructed to report early signs and/or symptoms of hepatotoxicity such as fever, rash, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, or jaundice. Chlorzoxazone should be discontinued immediately and a physician consulted if any of these signs or symptoms develop. Chlorzoxazone use should also be discontinued if a patient develops abnormal liver enzymes (e.g., AST, ALT, alkaline phosphatase and bilirubin.) The concomitant use of alcohol or other central nervous system depressants may have an additive effect. Usage in Pregnancy The safe use of chlorzoxazone has not been established with respect to the possible adverse effects upon fetal development. Therefore, it should be used in women of childbearing potential only when, in the judgment of the physician, the potential benefits outweigh the possible risks.
Contraindications
Chlorzoxazone is contraindicated in patients with known intolerance to the drug.
Adverse Reactions
Chlorzoxazone containing products are usually well tolerated. It is possible in rare instances that chlorzoxazone may have been associated with gastrointestinal bleeding. Drowsiness, dizziness, lightheadedness, malaise, or over-stimulation may be noted by an occasional patient. Rarely, allergic- type skin rashes, petechiae, or ecchymoses may develop during treatment. Angioneurotic edema or anaphylactic reactions are extremely rare. There is no evidence that the drug will cause renal damage. Rarely, a patient may note discoloration of the urine resulting from a phenolic metabolite of chlorzoxazone. This finding is of no known clinical significance. To report SUSPECTED ADVERSE EVENTS, contact Novitium Pharma LLC at 1-855-204-1431 or FDA at 1-800- FDA-1088 or http://www.fda.gov/ for voluntary reporting of adverse reactions.
Similar Drugs
Related medications based on brand, generic name, substance, active ingredients.